Serotonina pode piorar os sintomas de zumbido, aponta novo estudo

Uma nova pesquisa mostra que a serotonina, um neurotransmissor potencializado por muitos antidepressivos, pode intensificar o zumbido no ouvido. Cientistas identificaram um circuito cerebral específico em camundongos que associa níveis mais elevados de serotonina a comportamentos que mimetizam a condição.

Uma equipe da Oregon Health & Science University e da Universidade de Anhui, na China, publicou as descobertas no periódico Proceedings of the National Academy of Sciences. Os pesquisadores utilizaram optogenética para estimular neurônios produtores de serotonina e observaram um aumento da atividade em regiões auditivas do cérebro, juntamente com respostas semelhantes ao zumbido nos camundongos por meio de um teste de sobressalto modificado. O estudo complementa pesquisas anteriores de 2017 e coincide com relatos de alguns pacientes cujo zumbido piora com o uso de inibidores seletivos da recaptação da serotonina (ISRS).

Artigos relacionados

Lab participants show stress and irritability from inaudible infrasound in a scientific study, with visualized low-frequency waves and cortisol monitors.
Imagem gerada por IA

Study finds infrasound can raise cortisol and irritability even when people can’t hear it

Reportado por IA Imagem gerada por IA Verificado

A small controlled experiment reported in Frontiers in Behavioral Neuroscience found that exposure to infrasound—ultra-low-frequency vibration below the range of human hearing—was associated with higher salivary cortisol and more negative mood ratings, even though participants could not reliably detect when the infrasound was present.

Researchers have shown that stimulating specific brain activity in awake mice produces some of the restorative effects of deep sleep, including improved memory. The team now plans to explore whether a similar approach could work in people.

Reportado por IA

A widely studied anti-aging treatment triggered significant brain damage in mice, according to new research from the University of Connecticut. The drug combination dasatinib plus quercetin caused myelin loss and changes resembling those seen in multiple sclerosis. The findings raise questions about its use in longevity studies and off-label therapies.

A proof-of-concept randomized clinical trial published online May 20, 2026, in JAMA Psychiatry found signals that tocilizumab—an anti-inflammatory drug used for immune-mediated conditions including rheumatoid arthritis—may improve some symptoms in adults with moderate-to-severe depression who had a poor response to antidepressants and evidence of low-grade inflammation.

Reportado por IA

New research indicates that oestrogen levels, which vary across the menstrual cycle, can influence how efficiently some drugs reach the brain in women.

quarta-feira, 24 de junho de 2026, 11:25h

Brainstem neurons identified as key to blocking distractions

quarta-feira, 17 de junho de 2026, 08:16h

Plastic chemical exposure tied to adult anxiety in rats

quarta-feira, 03 de junho de 2026, 13:32h

Scientists reverse anxiety behaviors in mice by fixing brain circuit

domingo, 10 de maio de 2026, 05:49h

Scientists identify molecular switch that limits scratching

sexta-feira, 08 de maio de 2026, 20:50h

Slow breathing calms anxiety without mindfulness in mice study

segunda-feira, 27 de abril de 2026, 15:20h

Scientists identify brain circuit for chronic pain transition

Este site usa cookies

Usamos cookies para análise para melhorar nosso site. Leia nossa política de privacidade para mais informações.
Recusar